Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Dec 11, 2023

Oracle’s “Business Is Good and Getting Better”
Image Source: Peter Kaminski. On December 11, Oracle reported mixed second-quarter results for its fiscal 2024 that showed total revenue advancing 5% on a year-over-year basis (4% in constant currency), slightly lower than expectations, and non-GAAP earnings per share of $1.34 that came in slightly ahead of what the market was looking for. The company’s non-GAAP operating margin of 43% in the quarter helped to drive non-GAAP net income 14% higher than the same period a year ago (11% in constant currency). We’re not letting the slight miss on the top line sway us from our constructive stance on shares. Our fair value estimate stands at $108 per share, about in-line with where shares are currently trading.

Dec 10, 2023

First Gene-Editing Therapy Coming to Market; Reiterating Our Positive Stance on Vertex Pharma
Credit: Darryl Leja, NHGRI. On December 8, 2023, the U.S. Food and Drug Administration announced that it had approved Vertex Pharma’s and CRISPR Therapeutics’ novel gene-editing therapy (“Casgevy” – exa-cel) for sickle cell disease [SCD] in patients that are 12 years of age or older. This is the first such approval of its kind in U.S. history and will likely open the door for more gene-editing therapies for other rare diseases in the future. Estimates indicate that roughly 16,000 people will be eligible for the treatment at an estimated cost of around $2.2 million each, according to Reuters. The one-time market size of roughly $35.2 billion is a needle-mover, but the pace and timing of adoption of the therapy among the eligible population is difficult to estimate at this time. Note also that the therapy is of one-time application, meaning the therapy is a functional cure and will not be a source of recurring revenue from each patient. Nevertheless, it is an exciting development for medical science.

Dec 10, 2023

ESG Matters: Applied Materials Faces Criminal Investigation
Image: Applied Materials’ shares faced considerable pressure November 17 as news that it had violated export restrictions to China came to light. On November 16, Reuters reported that Applied Materials allegedly evaded export restrictions by shipping hundreds of millions of dollars of equipment to a subsidiary in South Korea before sending it to China’s biggest chipmaker SMIC. This alleged miscue falls under the Governance (G) category of ESG investing, and shares of Applied Materials have yet to recover from the aggressive sell-off it experienced during the trading session November 17. Though the results of the Department of Justice investigation are still pending, this is quite the black eye for Applied Materials, and we view this as a serious infraction given the U.S.’s stated efforts to keep advanced chips and chipmaking equipment out of China for national security reasons. We’re keeping a close eye on this story, as further news regarding the matter comes to light.

Dec 8, 2023

Dividend Increases/Decreases for the Week of December 8
Let's take a look at firms raising/lowering their dividends this week.

Dec 7, 2023

Latest Report Updates
Check out the latest report refreshes on the website.

Dec 5, 2023

5 Stocks to Consider Buying
The five stocks highlighted in this article generate tremendous amounts of free cash flow, have healthy balance sheets with either a net cash position or net-neutral position, generate high ROICs, and offer upside potential on the basis of the high end of our fair value estimate range. We think Apple and Microsoft are our two favorites, while Dick's Sporting Goods may be the one true "value" play with a low double-digit P/E ratio. Vertex Pharma has tremendous long-term potential, in our view, while shares of Booking Holdings appear cheap to us. We think the risk/reward remains in favor of the long-term investor that considers these five names.

Dec 3, 2023

Latest Report Updates
Check out the latest report refreshes on the website.

Nov 29, 2023

3 Dividend Growth Stocks For The Long Run
We think dividend growth investors should focus on total return first, and then move on to the evaluation of a company's dividend health. We believe that total return is a function of a company's net cash position and future expectations of free cash flow, and in this article, we have highlighted three strong, net-cash-rich, free cash flow generators that also have increased their dividends consistently over the years. Though these names are not hidden by any stretch, the strong performance of the Magnificent 7 reveals that investors don't need to look very far to find some of the best-performing ideas. Make sure that you know the Dividend Cushion ratio for companies in your dividend growth portfolio!

Nov 27, 2023

How Do We Use the Valuentum Buying Index?
Image: We highlighted Exxon Mobil to start 2022, and the stock was one of the best performers in the S&P 500 last year. Exxon Mobil became a “Valuentum” stock last year, with shares being undervalued, exhibiting a strong technical breakout, and sporting an attractive dividend yield to boot. The stock became a huge winner. Note: Exxon is no longer included in the simulated newsletter portfolios. The image is an excerpt from an email sent to members January 5, 2022.We answer one of the most frequently asked questions about the Valuentum Buying Index.

Nov 27, 2023

Nvidia’s Shares Could Run Higher Even More!
Image: Nvidia has been a market darling, and the firm's equity looks to have further upside potential on the basis of our valuation. On November 21, market darling Nvidia Corp. reported excellent fiscal third quarter results for the period ending October 29 that showcased the power behind the revolution in artificial intelligence. The company’s revenue hit a record, advancing more than three-fold on a year over year basis thanks to strength in its Data Center business. Its non-GAAP earnings were up six-fold from the year-ago period, and the firm continues to haul in tremendous free cash flow. We’ve raised our fair value estimate of Nvidia to $606 per share, and we think the company’s shares could continue to run higher.